摘要
目的观察小剂量高三尖杉酯碱+阿糖胞苷(LD—HA)诱导治疗非M3型老年急性髓系白血病(AML)的疗效和不良反应。方法将35例初治老年AML患者随机分为A组(19例)及B组(16例)。A组采用LD—HA方案:高三尖杉酯碱(H)1~2mg/d,阿糖胞苷(Ara—C)25mg,q12h,第1—14天化疗。B组采用标准剂量HA或DA方案。结果1个疗程结束后,A组和B组的完全缓解(CR)率分别为68.4%和37.5%;病死率分别为10.5%和18.7%,差异有统计学意义。血液学毒性两组差异无统计学意义;非血液学毒性的发生率A组低于B组。结论LD—HA诱导治疗老年AML近期疗效好,不良反应较轻。
Objective To observe the therapeutic outcome and adverse reaction of low-dose homoharringtonine and cytarabine ( LD-HA ) in the treatment of non-M3 acute myeloid leukemia ( AML ) in elderly patients. Methods 35 elderly patients with non-M3 AML were divided into group A (n= 19) and group B (n = 16) randomly. Group A was treated with LD-HA: homoharringtonine ( H ) 1-2 mg/d and Ara-C 25 mg, per 12 h, 1-14d, and group B was treated with the recommended dose HA or DA regimen. Results After one course of induction therapy, the complete remission (CR) rates of group A and B were 68.4% and 37.5%, respectively (P〈 0.05). The morbidity and mortality rates of group A were significantly lower than those of group B. There was no significant difference in bone marrow suppression between group A and B. Damages to the heart, liver, kidneys and digestive tract were significantly lower in group A than those in group B. Conclusion LD-HA schema offers a higher CR rate and has fewer adverse reaction in the treatment of non-M3 AML in elderly patients.
出处
《老年医学与保健》
CAS
2009年第3期152-153,共2页
Geriatrics & Health Care